Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial

Nizar M. Tannir, Pavlos Msaouel, Jeremy A. Ross, Catherine E. Devine, Anuradha Chandramohan, Graciela M.Nogueras Gonzalez, Xuemei Wang, Jennifer Wang, Paul G. Corn, Zita D. Lim, Lisa Pruitt, Jose A. Karam, Christopher G. Wood, Amado J. Zurita

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

This study is a head-to-head comparison between temsirolimus and an antiangiogenic agent as first-line treatment for advanced clear-cell renal cell carcinoma patients with clinical characteristics of poor prognosis. Efficacy was modest with both therapies, suggesting that their frontline use in unselected patients should be discouraged.

Original languageEnglish (US)
Pages (from-to)687-694
Number of pages8
JournalEuropean Urology Oncology
Volume3
Issue number5
DOIs
StatePublished - Oct 2020

Keywords

  • Cytokines and angiogenic factors
  • First line
  • International Metastatic Renal Cell Carcinoma Database Consortium risk groups
  • Pazopanib
  • Poor-risk metastatic renal cell carcinoma
  • Temsirolimus

ASJC Scopus subject areas

  • Surgery
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Urology

MD Anderson CCSG core facilities

  • Biostatics Resource Group

Fingerprint

Dive into the research topics of 'Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial'. Together they form a unique fingerprint.

Cite this